Hepatitis virus-related HCC patients with high levels of CDK1, CCNB1, PBK, ASPM, NDC80, AURKA, TPX2, KIF2C, and CENPF present a shorter overall survival (P < 0.05) which represents the time from randomization to death (Figures 7(a)–7(i)). This evidence concerns the gene ASPM and hepatocellular carcinoma.